Blog

Vivek Subbiah: “The hallmarks of cancer immune evasion” by Claudia Galassi et al.

Collage Photo of Claudia Galassi and Vivek Subbiah

Nov 9, 2024, 12:32

Vivek Subbiah: “The hallmarks of cancer immune evasion” by Claudia Galassi et al.

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on LinkedIn about recent paper by Claudia Galassi et al., titled “The hallmarks of cancer immune evasion” published on Cancer Cell.

Authors: Claudia Galassi, Timothy A. Chan, Ilio Vitale, Lorenzo Galluzzi

Vivek Subbiah: "The hallmarks of cancer immune evasion" by Claudia Galassi et al.

“‘The hallmarks of cancer immune evasion’ was just published in Cancer Cell

Nice overview of the immunoevasive phenotype.

The immunoevasive phenotype originates from various mechanisms that can be classified under a novel ‘three Cs’ conceptual framework:

1. Camouflage, which hides cancer cells from immune recognition,
2. Coercion, which directly or indirectly interferes with immune effector cells, and
3. Cytoprotection, which shields malignant cells from immune cytotoxicity.”

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.